|
ZA201703181B
|
|
Placental stem cell populations
|
|
WO2017117418A1
|
|
T lymphocyte production methods and t lymphocytes produced thereby
|
|
AU2016256718A1
|
|
Treatment of inflammatory diseases using placental stem cells
|
|
AU2016247217A1
|
|
Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
|
|
CN108368479A
|
|
Cell efficiency is analyzed
|
|
AU2016216517A1
|
|
Angiogenesis using placental stem cells
|
|
AU2016216536A1
|
|
Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
|
|
WO2016149492A1
|
|
Methods of banking placental tissue and cells
|
|
BR112017014098A2
|
|
platelet isolation methods
|
|
KR20170100653A
|
|
Methods of treating hematologic disorders, solid tumors, or infectious diseases using natural killer cells
|
|
AU2015271985A1
|
|
Methods of generating natural killer cells
|
|
AU2015268614A1
|
|
Treatment of stroke using isolated placental cells
|
|
AU2015258213A1
|
|
Treatment of diseases, disorders or conditions of the lung using placental cells
|
|
US2017240860A1
|
|
Method of producing erythrocytes
|
|
US2017252379A1
|
|
Placenta-derived adherent cell exosomes and uses thereof
|
|
EP3197467A1
|
|
Treatment of diabetic foot ulcer using placental stem cells
|
|
EP3191576A1
|
|
Methods for quantifying particulates in cell culture
|
|
WO2016033041A1
|
|
Extracellular matrix compositions
|
|
CN106795497A
|
|
It is engineered to go back to the nest to the CAR T lymphocytes of lymph node B cells area, skin or intestines and stomach
|
|
AU2015203846A1
|
|
Post-partum mammalian placenta, its use and placental stem cells therefrom
|
